PortfoliosLab logoPortfoliosLab logo
AQX.L vs. PBYI
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

AQX.L vs. PBYI - Performance Comparison

The chart below illustrates the hypothetical performance of a £10,000 investment in Aquis Exchange plc (AQX.L) and Puma Biotechnology, Inc. (PBYI). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Different Trading Currencies

AQX.L is traded in GBp, while PBYI is traded in USD. To make them comparable, the PBYI values have been converted to GBp using the latest available exchange rates.

Returns By Period


AQX.L

1D
1M
YTD
6M
1Y
3Y*
5Y*
10Y*

PBYI

1D
-2.18%
1M
-8.83%
YTD
14.88%
6M
30.52%
1Y
106.87%
3Y*
21.18%
5Y*
-8.63%
10Y*
-14.72%
*Multi-year figures are annualized to reflect compound growth (CAGR)

AQX.L vs. PBYI - Yearly Performance Comparison


2026 (YTD)20252024202320222021202020192018
AQX.L
Aquis Exchange plc
0.00%-100.00%91.10%-3.95%-39.68%34.04%16.92%-29.78%54.73%
PBYI
Puma Biotechnology, Inc.
14.88%81.18%-28.33%-2.75%55.69%-70.09%13.81%-58.64%-60.89%

Correlation

The correlation between AQX.L and PBYI is -0.02, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

-0.02

Correlation (3Y)
Calculated over the trailing 3-year period

0.02

Correlation (5Y)
Calculated over the trailing 5-year period

0.01

Correlation (All Time)
Calculated using the full available price history since Jun 15, 2018

0.02

Fundamentals

Total Revenue (TTM)

AQX.L:

£47.48M

PBYI:

$227.21M

Gross Profit (TTM)

AQX.L:

£15.81M

PBYI:

$169.14M

EBITDA (TTM)

AQX.L:

£8.52M

PBYI:

$46.97M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

AQX.L vs. PBYI — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

AQX.L

PBYI
PBYI Risk / Return Rank: 8383
Overall Rank
PBYI Sharpe Ratio Rank: 8282
Sharpe Ratio Rank
PBYI Sortino Ratio Rank: 7878
Sortino Ratio Rank
PBYI Omega Ratio Rank: 8484
Omega Ratio Rank
PBYI Calmar Ratio Rank: 8888
Calmar Ratio Rank
PBYI Martin Ratio Rank: 8686
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

AQX.L vs. PBYI - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Aquis Exchange plc (AQX.L) and Puma Biotechnology, Inc. (PBYI). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

AQX.L vs. PBYI - Sharpe Ratio Comparison


Loading charts...

Sharpe Ratios by Period


AQX.LPBYIDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

1.55

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.12

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

-0.18

Sharpe Ratio (All Time)

Calculated using the full available price history

-0.03

Drawdowns

AQX.L vs. PBYI - Drawdown Comparison


Loading charts...

Drawdown Indicators


AQX.LPBYIDifference

Max Drawdown

Largest peak-to-trough decline

-99.21%

Max Drawdown (1Y)

Largest decline over 1 year

-25.36%

Max Drawdown (3Y)

Largest decline over 3 years

-70.90%

Max Drawdown (5Y)

Largest decline over 5 years

-83.71%

Max Drawdown (10Y)

Largest decline over 10 years

-98.67%

Current Drawdown

Current decline from peak

-97.00%

Average Drawdown

Average peak-to-trough decline

-72.84%

Ulcer Index

Depth and duration of drawdowns from previous peaks

11.02%

Volatility

AQX.L vs. PBYI - Volatility Comparison


Loading charts...

Volatility by Period


AQX.LPBYIDifference

Volatility (1M)

Calculated over the trailing 1-month period

9.17%

Volatility (6M)

Calculated over the trailing 6-month period

40.95%

Volatility (1Y)

Calculated over the trailing 1-year period

69.20%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

75.32%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

80.62%

Dividends

AQX.L vs. PBYI - Dividend Comparison

Neither AQX.L nor PBYI has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

AQX.L vs. PBYI - Financials Comparison

This section allows you to compare key financial metrics between Aquis Exchange plc and Puma Biotechnology, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0020.00M40.00M60.00M80.00M100.00M202120222023202420252026
14.25M
44.80M
(AQX.L) Total Revenue
(PBYI) Total Revenue
Please note, different currencies. AQX.L values in GBp, PBYI values in USD

Frequently Asked Questions


AQX.L and PBYI have a correlation of -0.02, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Portfolio Optimizer

Find the right allocation for AQX.L and PBYI

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer